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ABSTRACT
Systemic mastocytosis (SM) pathology is extremely rare in canine practice, with insufficient reported data. The knowledge 
of the clinical behavior of this pathology is scarce. In human medicine, SM has been widely investigated, being defined 
as a rare hematopoietic disorder by the World Health Organization (2016), within the type of myeloproliferative 
neoplasms. Herein, we describe a systemic mastocytosis case in a Portuguese Serra-da-Estrela dog, where a cutaneous 
grade III/high-grade MCT was also diagnosed. The clinical decline of the animal and owner’s insistence throughout 
anamnesis that the dog was markedly different after the cytologic exam performed in another clinic, along with both severe 
eosinophilia and hepatomegaly, led to the clinical suspicion of SM. The animal passed away 7 days later. Post-mortem 
investigation confirmed SM pathology, and a deletion of 15 base pairs change on c-Kit gene exon 11 was identified. 
Contemplating the low number of cases described in the literature, this publication aims to disclose clinical and laboratory 
features of rare and poorly described canine SM, taking into consideration human outcomes described in the literature.
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RESUMO
A patologia da mastocitose sistêmica (SM) é extremamente rara na prática clínica canina, com escassos casos descritos 
na literatura científica. O conhecimento do comportamento clínico desta patologia é mínimo. Na medicina humana, 
a SM tem sido amplamente investigada, sendo definida como uma doença hematopoiética rara pela Organização Mundial 
da Saúde (2016), dentro do tipo de neoplasias mieloproliferativas. Descrevemos aqui um caso de mastocitose sistêmica 
num cão Serra-da-Estrela português, diagnosticado também com um mastocitoma cutâneo grau III / alto grau. O declínio 
clínico do animal e a insistência do proprietário durante a anamnese de que o cão estava marcadamente diferente após 
o exame citológico realizado em outra clínica, juntamente com eosinofilia e hepatomegalia graves, levantaram a suspeita 
clínica de SM. O animal faleceu 7 dias depois. A investigação post-mortem confirmou a patologia SM, e o estudo molecular 
revelou uma deleção de 15 pares de bases no exon 11 do gene c-Kit. Contemplando o baixo número de casos descritos 
na literatura, o objetivo desta publicação é divulgar características clínicas e laboratoriais de SM canina, levando em 
consideração informações clínicas descritas em humanos.
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Mast cell tumors (MCTs), also recognized as mastocytomas, 
are common in canine practice, representing up to 
16 – 21% of canine skin tumors (Blackwood et al., 2012). 
Mast cells (MCs) derive from hematopoietic lineage cells 
in the bone marrow, circulating in the blood and migrate 
into peripheral tissues, where they differentiate into mature 
MCs under the influence of various tissue-specific elements 
(Moon et al., 2014). MCs, also described as mastocytes, 
constitute an important host defense resident cellular 
population, frequent in the mucosal surfaces, often near 
epithelial cells, glands, smooth muscle cells, and nerves, and 
are widely distributed throughout the systemic bloodstream 
(Moon et al., 2014).
Mastocytosis involves the systemic proliferation of 
MCs, affecting the bone marrow, spleen, liver lymph nodes, 
gastrointestinal organs, and even skin in humans, dogs, 
and cats (Pariser & Gram, 2015).
In humans, mastocytosis has been widely investigated 
and is defined as a rare hematopoietic disorder. The World 
Health Organization (WHO) categorized mastocytosis 
within the type of myeloproliferative neoplasms (Wagner 
& Staubach, 2018). In humans, and rendering to the 
2016 WHO statement, mastocytosis is categorized in 
subvariants of cutaneous mastocytosis (with no systemic 
involvement), systemic variants (SM), and localized MCs 
tumors (Valent et al., 2017a). According to human data, the 
prognosis in cutaneous mastocytosis is defined as good, but 
the prognosis in SM is variable, alternating from indolent 
forms with normal life expectancy, to precipitously declining 
progressions (MetCalfe 2008; Valent et al., 2017b).
Nevertheless, SM is an extremely rare pathology in canine 
practice, with insufficient knowledge of the clinical behavior 
of this pathology. The lack of specific clinical manifestations 
in SM is pointed to as a sponsor for diagnostic adjournment.
This publication aims to disclose clinical and laboratory 
features of rare and poorly described canine SM, taking 
into consideration human outcomes.
Case Report
An 11-year old Portuguese canine breed Serra-da-Estrela 
male dog, having mostly an indoor habitat regime, was 
presented for consultation (day 1), referenced from 
another veterinary clinic (considered the day 0). The 
dog weighed 46 kg and presented a 4/9 body condition 
score (Freeman et al., 2011). According to the owner, the 
dog presented an enlarged abdomen within the last 24 h 
and was reticent to gait. The owner also mentioned that 
a cutaneous mass was subjected to a fine needle aspiration 
cytology, four days before, in the first assisting clinic. The 
owner insisted that, since this event, the animal has been 
apathetic, with evidently reduced food intake, and gasping. 
When interrogated, the owner confirmed the existence of 
pasty stools and an aqueous regurgitation immediately after 
water intake, three days and 4 h beforehand, respectively.
At the consultation, the dog presented a dilated abdomen, 
a respiratory rate of 47 breaths/minute, a cardiac frequency of 
132 beats/minute, intense pink colored mucous membranes 
with a refiling time of 2.5 sec. The canine was hydrated, 
presenting 38.7 ºC rectal temperature. The dog was conscious, 
reactive to stimuli, but lethargic. No abnormal sounds were 
detected in the cardio-pulmonary auscultation exam. Fluid 
therapy was performed with intravenous Ringer lactate 
solution, at a rate of 145 mL/ hour, through a peripheric 
cephalic venous catheter. Oxygen was given through a nasal 
cannula. The canine presented a moderate hypertensive 
state (Acierno et al., 2018).
From the historical record of the patient, there were 
sudden episodes of syncope, five years earlier, associated 
with hypoglycaemic states, presumably related to long 
fasting periods due to behavioral issues. Two years before, 
the animal was diagnosed with degenerative joint disease, at 
the level of its left shoulder and both hip joints, conducting 
at that time, intra-articular treatment with autologous 
bone-marrow aspiration concentrate combined with 
platelet concentrate. Over the past six months, the dog was 
receiving daily a commercialized veterinary complement 
of hemp oil, regularly, with intermittent intervals for six 
consecutive days of firocoxib as an integrated protocol for 
pain rescue (approximately one episode within two months 
period, according to the owner). The patient had an updated 
vaccine and both internal and external deworming protocols, 
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including heartworm and leishmaniosis prevention. The 
results of a complete medical check-up performed 10-months 
earlier were unremarkable.
Hematological analysis revealed neutrophilia, prominent 
eosinophilia, mild azotemia, hypoproteinaemia, and 
increased prothrombin time (PT) (Table  1). Pericardial 
and cardiac morphologic abnormalities were ruled out by 
cardiac ultrasound. Abdominal ultrasound disclosed severe 
hepatomegaly, with the caudate hepatic lobe reaching the 
right caudal quadrant of the abdomen, passing the cranial 
limits of the urinary bladder, enlargement of the spleen, and 
local lymph nodes, and an abdominal 4 points fluid score. 
Both liver and spleen disclosed a diffuse homogeneous 
hypoechoic parenchymal pattern.




DAY 0 DAY 1 DAY 3
HEMATOLOGICAL ANALYSIS
RBC (x1012 cells/L) 6.58 6.91 NP 5.65 – 8.87
Haematocrit (%) 45.8 44,5 39 37.3 – 61.7
Haemoglobin (g/L) 153 158 NP 131 – 205
MCV (fL) 69.6 64.4 NP 61.6 – 73.5
MCH (pg) 23.3 22.9 NP 21.2 – 25.9
MCHC (g/dL) 335 355 NP 320 – 379
RDW (%) 15.1 19.4 NP 13.6 – 21.7
% Reticulocyte NP 0.5 NP %
Reticulocyte (K/µL) NP 31.8 NP 10 – 110
CHr (pg) NP 29.8 NP 22.3 – 29.6
Total WBC (x109 cells/L) 16.18 22.25 NP 5.05 – 16.76
Neutrophils (x109 cells/L) 9.71 13.71 NP 2.95 – 11.64
Lymphocytes (x109 cells/L) 1.42 1.82 NP 1.05 – 5.10
Monocytes (x109 cells/L) 1.28 1.87 NP 0.16 – 1.12
Eosinophils (x109 cells/L) 3.75 5.11 NP 0.06 – 1.23
Basophils (x109 cells/L) 0.02 0.04 NP 0.00 – 1.10
Platelets (x109 cells/L) 176 171 NP 148 – 484
PDW (fL) 15.7 12.3 NP 9.1 – 19.4
MPV (fL) 9.9 12.3 NP 8.7 – 13.2
Plateletcrit (%) 0.175 0.21 NP 0.14 – 0.46
BIOCHEMICAL ANALYSIS
Creatinine (mg/dL) 1.52 1.42 NP 0.40 – 1.40
Urea (mg/dL) 36.2 27.4 NP 9.2 – 29.2
Glucose (mg/d) 134 NP NP 75 – 128
ALP (UI) 41 NP NP 13 – 83
ALT (UI) 27 NP NP 17 – 78
Albumin (g/dL) 2.5 NP NP 2.6 – 4.0
Total Protein (g/dL) 5.7 5.6 NP 5.0 – 7.2
Globulin (g/dL) 3.2 NP NP 1.6 – 3.7
Alb/Glob ratio 0.8 NP NP 0.7 – 1.9
BUN/Creatinine 23.8 19.3 NP 12.5 – 31.8
COAGULATION PROFILE
PT (seconds) NP NP 8.3 5.1 – 7.9
APTT (seconds) NP NP 12.3 8.6 – 12.9
Fibrinogen (mg/dL) NP NP 195.4 150.0 – 300.0
URIANALYSIS
USG NP 1.040 1.034 1.012 – 1.030
Colour and Clarity NP Yellow, clear Yellow, clear Ambar, clear
pH NP 7 NP 5 – 7.5
Protein NP 1+ NP Negative
Glucose NP Negative NP Negative
Ketones NP Negative NP Negative
Bilirubin NP Negative NP Negative/1+
Urobilinogen NP Negative NP Negative
Blood NP 1+ (RBC) NP Negative
Nitrites NP Negative NP Negative
Urine sediment cytology NP No sediment NP Absent
Abbreviations: APTT, activated partial thromboplastin time; NP, not performed; PT, prothrombin time; RBC, red blood cells; USG, urine specific gravity; WBC, 
white blood cells. *) Hematological analysis performed by ProCyte DX Haematology Analyzer (IDEXX, USA); Coagulation profile performed by coagulometer 
Sysmex CA-450; Biochemical analyses performed using DRI-CHEM 4000i (FUJIFILM, USA). The reference ranges were recommended by the respective 
manufacturers and previously clinical and scientifically validated.
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Figure 1 – Microphotographs of cavitary fluid, buffy coat smear, cutaneous mass, and liver cytologic examinations of the dog. (A) 
Sterile eosinophilic abdominal effusion with moderate cellularity, red blood cells, non-degenerate neutrophils, eosinophils 
(> 20%), and occasional mesothelial cells (inset); lymphocytes and macrophages were visualized and no evident MCs 
were detected on the microscopic examination; (B) Buffy coat smear of the patient, demonstrating mastocyte presence 
(arrow); (C) Liver fine needle cytology, revealing poorly granulated mastocytes disposed of with the resident hepatic 
cells; eosinophils were also identified; (D) Cutaneous mass non-aspirate cytology, characterized by a cluster of mastocytes 
with poorly granular cytoplasm and prominent nucleoli, suggesting a poorly differentiated cutaneous mast cell tumor, 
confirmed by histological analysis, showing an extensive and infiltrative proliferation of atypical mast cells, with scarce 
intracytoplasmic granulation, marked anisokaryosis and pleomorphism, intermingled with few eosinophils (inset); (E) 
Cytoplasmatic KIT immunohistochemical staining, pattern III of cutaneous MCT; (F) Nuclear immunohistochemical 
staining in neoplastic cells of cutaneous MCT. A-D, Romanowsky stain; bar = 20 µm. E, IHQ, Ki-67; bar = 20 μm. F, 
IHQ, CD117; bar = 20 μm.
Abdominocentesis drained 370 mL of a yellow-reddish 
fluid, classified as a sterile eosinophilic effusion (Figure 1A). 
Considerable MCs were observed on the blood smear 
preparation of the buffy coat (Figure 1B).
Considering the hypothesis of an MCTs degranulation 
event, the therapeutic plan was implemented, consisting of 
diphenhydramine hydrochloride 1 mg/kg IM q12 h, ranitidine 
2 mg/kg SC q12 h, prednisolone 1.5 mg/ kg PO q12 h, omeprazole 
5/7
Braz J Vet Res Anim Sci. 2021;58:e175896
1 mg/kg PO q24 h and benazepril 0.5 mg/kg PO q24 h PO. 
Tramadol 4mg/Kg q 12 h SC was administered for two 
days due to abdominal discomfort on palpation exam. 
Amoxicillin with clavulanic acid (20 mg/kg SC q12 h) 
was administrated due to neutrophilia and monocytosis.
Four hours later the patient was without oxygen therapy 
support. Food intake was performed voluntarily after 
5 h of hospitalization.
Non-aspirate fine needle cytology of the cutaneous 
mass was performed, for the validation of the first cytology 
performed in the first attending clinic, after a gentle 
cleansing of the skin. The 2 x 3 cm mass was minimally 
manipulated, revealing no mobility at the palpation, with 
a firm and hard consistence, irregular shape, localized in 
the dorsal lumbar-sacral cutaneous region.
Microscopic analysis of the mass revealed abundant 
cellular content, constituted by mastocytes, with poorly 
granulated cytoplasm. Multinucleation and anisokaryosis 
were observed. Nuclear pleomorphism was present, 
characterized by nonrounded nuclear forms. Eosinophils 
were identified, disposed of within the cellular population 
(score 3+). Cytologic evaluation of the cutaneous mass 
(Figure 1C) was compatible with a high-grade mast cell 
tumor (Camus et al., 2016).
Considering the clinical stabilization of the patient 
and targeting the lesion excision for its classification and 
selection of probable chemotherapeutic plan, the dog was 
submitted to general anesthesia. The excision of the cutaneous 
mass and guided-ultrasound non-aspirate liver cytology 
were performed (Figure  1D). The surgery was without 
complications. Five hours after the surgery, the animal was 
lethargic, and oxygen therapy was provided. The animal 
became stuporous and died within 24 h after the surgery.
A cosmetic necropsy was performed following the owner’s 
approval. The post-mortem examination revealed the presence 
of multiple poor-delimitated nodules disseminated on the 
liver, spleen, and lymph nodes, and hemorrhagic effusion. 
The liver aspirate cytology revealed profuse poorly granulated 
mastocytes disposed of with the resident hepatic cells and 
eosinophils were also identified. Post-mortem histopathological 
examination confirmed visceral mastocytosis diagnosis, 
revealing an extensive and infiltrative proliferation of atypical 
mast cells, with scarce intracytoplasmatic granulation, marked 
anisokaryosis and pleomorphism, with a high mitotic count 
(>6/10 HPF) compatible with a high-grade mast cell tumor 
(Kiupel et al., 2011).
Immunohistochemical analysis revealed a diffuse 
cytoplasmatic KIT staining - pattern III. Ki-67 
immunohistochemical analysis revealed an average positive 
cell per gird area above 23 which is considered a high 
index (Figure 2). An identical neoplastic population was 
found disseminated on the liver, spleen, and lymph nodes, 
confirming a diagnosis of visceral mastocytosis (Figure 2).
Possible mutations on multiple exons of the c-Kit 
gene were analyzed by PCR technique, namely on exons 
8,9,11,14 e 17. A deletion of 15 base pairs (bp) on the c-Kit 
gene exon 11 was identified. On remaining exons, the results 
were as follows: on exon 17 absence of punctual mutation 
A813P and D815H; on exon 8 absence of punctual mutation 
Q430R, internal tandem duplications (ITD), insertions or 
deletions; on exon 9 absence of punctual mutations S479I, 
N508I and A510V, and on exon 14 absence of punctual 
mutation T669I.
Discussion
SM, also designed as visceral mastocytosis, is a rare, 
highly lethal, and poorly reported disorder in canine practice. 
The marked eosinophilia and increase of circulating MCs in 
the bloodstream were the diagnostic clues that reinforced 
the clinical suspicion of the SM in this case. Moreover, 
gastrointestinal signs were subtle. Recurrent syncope 
episodes are reported in human SM, explained by the 
Figure 2 – Microphotographs from immunohistochemical staining from abdominal organs of the dog. (A) KIT immunohistochemical 
staining (pattern III) on disseminated neoplastic MCs on lymph node (IHQ, CD117; bar = 50 μm); (B) KIT 
immunohistochemical staining (pattern III) on disseminated neoplastic MCs on the liver (IHQ, CD117; bar = 50 μm); 
(C) KIT immunohistochemical staining (pattern III) on disseminated neoplastic MCs on spleen (IHQ, CD117; bar = 50 μm).
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vasodilatation sponsored by MCs mediators (Akin, 2017). 
Our canine also presented a history of syncope episodes, 
during a limited period.
Based on human findings, the association between 
cutaneous forms of mastocytoma and SM is currently 
accepted, and some studies have suggested that cutaneous 
MCTs may be a predictive factor for SM (O’Keefe et al., 
1987). Nevertheless, the absence of cutaneous MCTs in 
veterinary patients with SM is possible, also designated 
as primary visceral mastocytosis, being more common 
in cats (Takahashi et al., 2000). A clinical study involving 
10 canine visceral mastocytosis cases without skin 
involvement, identified MCTs masses localized at the 
intestinal region in 6 cases, being impossible to localize the 
tumor in three dogs (Takahashi et al., 2000). Additionally, 
the same work suggested a predisposition of male dogs 
for SM and a considerable post-surgery mortality rate 
(Takahashi et al., 2000). Paraneoplastic signs are frequently 
described in aggressive forms of MCTs, being associated 
with the degranulation of the tumor, causing the release 
of biologically active substances, that promotes a rapid 
influx of calcium ions into the cells (Blackwood et al., 2012; 
Misdorp, 2004). The authors believe that the advanced 
stage of the disease (SM) determined the clinical decline 
of the patient, with no contribution of the cytological exam 
performed in the first assisting clinic. Clinical signs related 
to degranulation occurrence are more frequently related to 
visceral or disseminated MCTs (Blackwood et al., 2012).
Some studies showed that MCTs with mutations in exon 
11 tend to be more aggressive tumors (Tamlin et al., 2019). 
Studies on canine cutaneous MCTs were reported in the 
same exon deletions in a few base-pairs (bp), but deletions 
in 21 bp were reported in one research (Tamlin  et  al., 
2019). Proto-oncogene c-Kit mutational status is conserved 
between any primary and its matched secondary tumor, 
suggesting that both can be used for c-Kit mutational testing 
(Marconato et al., 2014).
The similarities between human and canine lethal SM 
are surprising. Mutations in the c-Kit region are frequently 
identified in neoplastic MCs of dogs, humans, and even 
cats, contributing to mast cell carcinogenesis (Tamlin et al., 
2019). The advance on human SM may benefit veterinary 
patients through the application of translational approaches, 
with the administration of specific chemotherapy agents 
that have recognized benefits in the disease, namely 
tyrosine kinase inhibitors, based on the mutation of the 
c-Kit region expressed by neoplastic cells (Nakano et al., 
2017). Conversely, recent molecular findings reveal that 
most human SM cases express the D816V-mutated variant 
of KIT, conferring resistance against several tyrosine kinase 
inhibitors (TKI), such as imatinib. Even so, c-Kit screening 
is always recommended in veterinary settings. Human 
cases of aggressive SM conversion into myeloproliferative 
neoplasm have been treated with combined advanced 
therapies such as allogeneic hematopoietic stem cell 
transplantation, poorly explored in veterinary medicine 
(Wagner & Staubach, 2018).
Conclusion
To our knowledge, this is the first report of systemic 
mastocytosis in a Portuguese canine breed, being one of 
the few describing both clinical and laboratory features 
associated with this pathology.
The execution of complementary exams for mastocytosis 
confirmation such as the liver, spleen, and accessible regional 
drainage lymph nodes sampling for cytologic evaluation is 
recommended to assume the clinical decisions, and for a 
diagnostic procedure, especially in cases where an increase 
of circulating MCs in the bloodstream and both severe 
eosinophilia and hepatosplenomegaly are detected. Medical 
treatment based on prednisolone, diphenhydramine, and 
H1/H2 antagonist, and even chemotherapy once the disease 
is detectable is encouraged. Moreover, even with a poor 
prognosis, an early implementation of a chemotherapeutic 
plan should be pondered, considering the unavoidable time 
delay inherent to the obtainment of conclusive laboratory 
results.
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